Thyroid Cancer
October 30
4 min read
Updated results of the phase III LIBRETTO-531 trial showed durable benefits with selpercatinib compared with existing targeted therapies for advanced RET-mutant medullary thyroid cancer, while primary results from a phase II trial demonstrated safety and antitumor activity for sacituzumab govitecan in advanced or metastatic differentiated or anaplastic thyroid carcinoma.